IRX5183

IRX5183 is an orally bioavailable small molecule with highly selective RARα agonist profile. It has successfully completed phase I clinical trials in over 40 patients solid tumors and leukemias. Current focus of the program is on development of IRX5183 for the treatment of myeloid leukemias, and multiple myeloma.